Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,600.00-0.34%ETH$2,697.97-0.63%GOLD$4,192.70+0.86%OIL$89.91+0.54%
Smart Investors Daily
SID Premium
LG

NASDAQ · LGVN

Longeveron Inc. Common Stock

Healthcare · Biotechnology

$2.51

Down-$0.16 (-6.37%)

Updated Oct 6, 2026, 9:41 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
13.34M
P/E ratio
-0.54
Dividend yield
0.00%
52-week range
$0.49 – $8.70
Volume
44.16K
Avg. volume
453.73K

Price performance · LGVN

LGVN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

LGVN closed at $2.51 after 20 trading sessions, down 62.26% for the selected period.

Last close
$2.51
Period change
-62.26%
Period low
$2.45
Period high
$7.33
Daily close
View OHLC price history
LGVN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$2.59$2.6919$2.51$2.5144.16K
Oct 2, 2026$2.56$2.675$2.54$2.5820.81K
Oct 1, 2026$2.72$2.74$2.52$2.5972.96K
Sep 30, 2026$2.73$2.80$2.61$2.6954.97K
Sep 29, 2026$2.68$2.74$2.604$2.7255.2K
Sep 28, 2026$2.79$2.79$2.622$2.63102.03K
Sep 25, 2026$2.89$2.95$2.76$2.8150.53K
Sep 24, 2026$2.54$2.97$2.50$2.91172.84K
Sep 23, 2026$2.68$2.7599$2.53$2.6062.31K
Sep 22, 2026$2.47$2.83$2.32$2.72233.99K
Sep 21, 2026$2.49$2.54$2.33$2.45171.73K
Sep 18, 2026$2.80$2.80$2.3001$2.49527.17K
Sep 17, 2026$3.23$3.35$2.70$2.711.44M
Sep 16, 2026$6.83$7.15$6.52$6.68316.65K
Sep 15, 2026$6.89$7.10$6.65$6.8644.38K
Sep 14, 2026$7.195$7.60$6.92$6.9261.88K
Sep 11, 2026$6.79$7.3597$6.64$7.3368.15K
Sep 10, 2026$6.52$6.7999$6.50$6.6459.57K
Sep 9, 2026$6.58$6.75$6.51$6.5829.57K
Sep 8, 2026$6.78$6.90$6.56$6.6550.15K

Latest LGVN news

The latest Smart Investors Daily articles mentioning LGVN.

Stock researchCompany · Overview

LGVN research

Overview

Company profile and research snapshot.

Company profile

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
LGVN recent ratings
DateFirmRatingTarget
May 11, 2026Maxim GroupHold—
May 4, 2026HC Wainwright & Co.Buy—
Aug 15, 2025Roth CapitalBuy—
Mar 21, 2025HC Wainwright & Co.Buy—
Mar 3, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxivMIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longe

Yahoo · Sep 22, 2026

Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?

Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study evaluated laromestrocel as an adjunct to Stage 2 palliative heart surgery. The primary endpoint measured change in right ventricular ejection fraction, an indicator of pumping […]

Benzinga · Sep 18, 2026

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose 20.43% to

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By